RheoGene Introduces AttSite Recombinases for Site-Specific DNA Modification

Strategic Insights -

RheoGene Inc. has revolutionized the field of gene-targeting enzymes with the introduction of AttSite Recombinases, a novel platform that enables site-specific DNA modification in a broad range of organisms. This innovative technology has far-reaching applications in functional genomics, transgenics technology, biotherapeutic protein production, and stem cell and gene therapy. Thomas Tillett, RheoGene CEO, emphasizes the significance of AttSite Recombinases, stating that they represent a new generation of gene-targeting tools for life sciences research and product development.

Key Takeaways:

  • AttSite Recombinases are novel gene-targeting enzymes that catalyze irreversible integration or excision of DNA sequences at specific locations within the genome.
  • Each enzyme recognizes a different DNA sequence, allowing for the use of multiple enzyme combinations to introduce multiple genes into the same site in the genome or into different sites in the same cell.
  • The platform provides precision and flexibility, enabling researchers to make targeted genetic modifications at stable, well-characterized loci.
  • AttSite Recombinases have significant applications in functional genomics, transgenics technology, biotherapeutic protein production, stem cell therapy, and gene therapy.
  • Nonexclusive research and commercial licenses for AttSite Recombinases are available from RheoGene.
  • The AttSite Recombinase program was supported in part by a NIST-ATP grant awarded to RheoGene in 2001.
  • RheoGene's two current platforms, RheoSwitch inducible gene expression technology and AttSite Recombinases, offer targeted, regulated solutions to accelerate pharmaceutical development from discovery to the clinic.
  • The RheoSwitch system features tight gene regulation, rheostatic control, and an expression range from complete 'off' to maximal levels equivalent to strong viral promoters.

Statistics:

  • 2001: NIST-ATP grant awarded to RheoGene to support the AttSite Recombinase program.
  • RheoGene's AttSite Recombinases platform offers precision and flexibility in making targeted genetic modifications at stable, well-characterized loci.
  • RheoGene's two current platforms, RheoSwitch inducible gene expression technology and AttSite Recombinases, are available for accelerating pharmaceutical development from discovery to the clinic.

Sources:

  • RheoGene Inc., (press release), "RheoGene Announces Introduction of AttSite Recombinases"
  • Thomas Tillett, RheoGene CEO, as quoted in RheoGene press release
  • Alan Russell PhD, director of the McGowan Institute for Regenerative Medicine and chairman of RheoGene's scientific advisory board, as quoted in RheoGene press release
  • Health & Medicine Week, 2005, "RheoGene Introduces AttSite Recombinases for Site-Specific DNA Modification"